Zanaletti et al. developed a new α7 nicotinic acetylcholine receptors (α7 nAChR) represented promising therapeutic candidates for the treatment of cognitive impairment associated with Alzheimer’s disease (AD) and schizophrenia. Here, CHRNA7 is linked to Cognitive impairment.